McDonald C, Lipp J
Austin & Repatriation Medical Centre, Heidelberg, Victoria.
Aust Fam Physician. 1998 Jan-Feb;27(1-2):64-8, 70.
Asthma management is changing, and there are many potential new drugs undergoing early and late phase trials. Nonetheless, it is unlikely that any dramatic alterations in therapy will occur within the next 3 years. The asthma treatment paradigm has altered over the past 10 or so years, with the emphasis on symptom relief from short acting beta agonists giving way to preventive treatment of underlying airway inflammation with inhaled corticosteroids. More recently, long acting beta agonists have been demonstrated to reduce the need for increasing doses of inhaled steroids in patients with poorly controlled asthma. This article reviews these trends.
哮喘管理正在发生变化，有许多潜在的新药正处于早期和晚期试验阶段。尽管如此，在未来3年内治疗方法不太可能出现任何显著变化。在过去约10年里，哮喘治疗模式已经发生改变，从强调使用短效β受体激动剂缓解症状，转变为使用吸入性糖皮质激素对潜在气道炎症进行预防性治疗。最近，长效β受体激动剂已被证明可减少哮喘控制不佳患者增加吸入性类固醇剂量的需求。本文对这些趋势进行综述。
